BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Breathing Circuits Market – Forecast to 2028,’ thoroughly examines the Breathing Circuits industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Ambulatory Surgery Center (ASC) Market – Forecast to 2028,’ thoroughly examines the Ambulatory Surgery Center (ASC) industry to provide essential data & information for the targeted readers.

The global defibrillator market size is expected to reach USD 13.54 Billion by 2028, at a CAGR of 3.4% over the forecast period, according to the current analysis of Reports and Data.

The global hollow fiber filtration market size is expected to reach USD 881.53 Million by 2028 at a CAGR of 13.8%, according to the latest report by Reports and Data.

The global human liver models market size is expected to reach USD 5.5 Billion by 2028 and register a CAGR of 13.9% over the forecast period, according to the latest report by Reports and Data.

Predictive Health Diagnostics Company, Inc. announced the appointment of Susie Lu as President of Laboratory Services for all Predictive Health Diagnostics Company businesses.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency

Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations.

Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company, announced that the sales of the antifungal Cresemba® by its license partner Pfizer Inc. in the Asia Pacific region, exceeded the threshold triggering the first sales milestone payment for this region of USD 1.25 million.

Addex Therapeutics Ltd announced that it has terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson’s disease due to the slow recruitment of patients.